


Role of HTA in Decision Making



Health Canada

Is it safe? Does it work?



CADTH

How does it compare to existing treatment options?



Ministries/Public Insurance Plans

Is it worth it?
Can we afford it?

CADTH Scientific Advice Program

- Established January 2015
- Voluntary, fee-for-service, confidential, non-binding
- Inform clinical trial design so evidence generated is meaningful from Canadian and HTA perspective
- Face-to-face meeting to discuss advice and written record of advice

Patients Engaged as Experts

- Developed with CADTH Patient Community Liaison Forum
- Non-disclosure agreement and paid honoraria
- Ask patient groups to find individual with:
 - Experience with disease similar to trial population
 - Experience with multiple therapies
 - Aware of other's experiences

Ethical Engagement

- Multi-part engagement and consent process
- Plain language consent form
- Individuals in control of information shared and can stop or redact information
- Conflict of interest disclosure signed before interview

Patients Tell Us About...

- Impact of health condition
- Experiences with previous and current therapy
- Challenges with current therapies
- Opinion on importance of various PROMs for assessing new therapy

Patient Involvement

- 1-hour interview
- Semi-structured questions tailored for disease area and advice sought
- Written summary of interview included in record of scientific advice
- Accuracy confirmed by individual; personal identifiers removed
- Individual input compared and contrasted with patient groups input from past CADTH Drug Reviews

To Date

- Patient perspectives most important in development of advice regarding outcomes, particularly quality of life measures
- Illustrates the condition and treatment experiences to CADTH researchers who do not routinely see patients

More Information?

Amy Sood, Manager Scientific Advice

AmyS@cadth.ca

CADTH Evidence
Driven.

ACMETS Preuves
à l'appui.